ZP-8396/CT-388 / Zealand Pharma, Roche - LARVOL DELTA

Upcoming events in the second half of 2026 (GlobeNewswire) - "Petrelintide, amylin analog. In H2 2026, Zealand Pharma and Roche expect to initiate registrational Phase 3 trials with petrelintide monotherapy; Petrelintide, amylin analog. In H2 2026, Zealand Pharma expects to report topline results from the Phase 2 ZUPREME-2 trial in people with overweight or obesity and type 2 diabetes; Petrelintide/enicepatide (CT-388), amylin+GLP-1/GIP fixed-dose combination. Zealand Pharma and Roche expect to initiate the Phase 2 ZYNERGY trial in people with overweight or obesity in H2 2026."

New P3 trial • P2 data • Trial status • Obesity • Type 2 Diabetes Mellitus

A Phase 2 trial exploring the combination of petrelintide and CT-388 will be initiated in the first half of 2026. (GlobeNewswire)

New P2 trial • Obesity

Petrelintide/CT-388, amylin+GLP-1/GIP combination (GlobeNewswire) - "Zealand Pharma and Roche expect to initiate Phase 2 with petrelintide/CT-388 in the first half of 2026."

New P2 trial • Obesity

Petrelintide/CT-388, amylin+GLP-1/GIP fixed-dose combination. Zealand Pharma and Roche expect to initiate Phase 2 with petrelintide/CT-388 in the first half of 2026. (GlobeNewswire)

New P2 trial • Obesity

Upcoming events next 12 months (GlobeNewswire) - "In the first half of 2026, Zealand Pharma expects to report topline results from the Phase 2 ZUPREME-1 trial and complete the Phase 2 ZUPREME-2 trial with petrelintide...Zealand Pharma and Roche expect to initiate Phase 2 with petrelintide/CT-388 in the first half of 2026...In the second half of 2025, Zealand Pharma expects to initiate a Phase 2 trial in a dedicated obesity-related comorbidity....Topline data from SYNCHRONIZE-1 and SYNCHRONIZE-2, the Phase 3 trials with survodutide in people with overweight or obesity without and with type 2 diabetes, respectively, are expected in the first half of 2026."

Clinical data • New P2 trial • Trial status • Obesity • Type 2 Diabetes Mellitus